Rectal Ketamine Administration: Uses in Pediatric and Palliative Care

Rectal ketamine administration delivers the drug through the rectal mucosa, where it absorbs into the bloodstream and reaches roughly 25-30 percent bioavailability, with effects starting in 10-20 minutes. This route is far less common than intravenous, intramuscular, or oral and sublingual ketamine, but it holds an established place in two specific clinical settings: pediatric procedural sedation and palliative or hospice pain management.

Rectal ketamine administration is not a standard treatment for depression, PTSD, or other psychiatric conditions. Those protocols rely on IV, intramuscular, sublingual, or intranasal esketamine instead. Clinicians choose the rectal route mainly when a patient cannot take medication by mouth, intravenous access is difficult or unavailable, and a relatively fast onset is still needed. This guide explains how rectal ketamine is absorbed, how it is dosed and formulated, and how it compares with other routes covered in our complete guide to ketamine.

Pharmacokinetics of Rectal Ketamine

Bioavailability

The rectal bioavailability of ketamine is approximately 25-30 percent, comparable to sublingual administration and somewhat higher than swallowed oral ketamine, which ranges from 17-24 percent. See our full explanation of ketamine bioavailability for how these numbers compare across every route.

This intermediate bioavailability reflects a dual absorption pattern within the rectum. Drug absorbed in the lower rectum enters the inferior and middle rectal veins, which drain into the systemic circulation via the internal iliac veins, largely bypassing the liver and avoiding first-pass metabolism. Drug absorbed higher in the rectum enters the superior rectal vein, which drains into the portal system and subjects the dose to hepatic first-pass metabolism instead. Because distribution within the rectum varies by patient, technique, and insertion depth, the extent of first-pass avoidance is inconsistent, which produces more bioavailability variability than IV or IM administration.

Onset and Duration

• Onset of action: 10-20 minutes, faster than swallowed oral administration (20-45 minutes) but slower than IV (immediate) or IM (3-5 minutes)
• Peak plasma concentration: typically reached within 20-45 minutes
• Duration of clinical effect: 60-120 minutes for sedation; analgesic effects may last longer
• Half-life: approximately 2-3 hours, consistent with other administration routes

Metabolism

Once absorbed, rectal ketamine follows the same metabolic pathway as other routes. Hepatic CYP3A4 and CYP2B6 enzymes convert it to norketamine, its primary active metabolite, through N-demethylation. According to a pharmacokinetic study in the British Journal of Anaesthesia, plasma ketamine and norketamine concentrations after rectal dosing in children track closely with concentrations measured after IV and nasal administration, though the rise is slower (Malinovsky et al., 1996, indexed on PubMed).

Clinical Applications

Pediatric Sedation

Rectal ketamine has its most established role in pediatric medicine. Young children, particularly those under age 5, may be unable or unwilling to take oral medications, may have difficult intravenous access, and may become distressed by injections. Rectal administration offers a non-invasive route that avoids needles and does not require patient cooperation.

Common pediatric applications include:

• Procedural sedation for brief procedures such as laceration repair, fracture reduction, imaging studies like CT or MRI, and burn dressing changes
• Preoperative sedation to reduce anxiety and ease separation from parents before surgery
• Emergency department use when rapid sedation is needed and IV access has not yet been established

Typical pediatric dosing for rectal ketamine ranges from 5-10 mg/kg, substantially higher than IV sedation doses of 1-2 mg/kg, to compensate for lower bioavailability. It is usually given as a solution or suppository. The American Academy of Pediatrics publishes guidance on procedural sedation practices in children, including monitoring standards relevant to rectal dosing, available through the AAP.

Palliative and End-of-Life Care

Rectal ketamine also has a role in palliative medicine, particularly for patients who cannot swallow due to advanced illness, nausea, or oropharyngeal dysfunction; have limited or no intravenous access; are receiving home-based hospice care where IV administration is impractical; or have refractory pain that has not responded to conventional opioid therapy.

In palliative settings, ketamine is often used as an adjuvant analgesic for severe, opioid-resistant pain, particularly pain with a neuropathic component. Its NMDA receptor antagonism can address pain signaling pathways that opioids alone do not resolve.

Veterinary Medicine

Rectal ketamine is also used in veterinary medicine to sedate small animals and wildlife when injection is hazardous or impractical. This use is not directly relevant to human clinical care, but veterinary pharmacokinetic data has contributed to the broader understanding of rectal ketamine absorption.

Formulations

Solutions

The most common rectal ketamine formulation is a liquid solution, administered with a needle-free syringe or a rectal catheter. Standard injectable ketamine solution, typically 50 or 100 mg/mL, is commonly diluted to an appropriate volume and instilled 2-4 centimeters into the rectum.

Suppositories

Compounded ketamine suppositories are available from compounding pharmacies and offer a solid dosage form that is easier to retain. They are typically formulated in a cocoa butter or polyethylene glycol base and can be prepared in precise doses, which makes them a practical option for palliative care patients receiving repeated dosing at home.

Gels

Some compounding pharmacies prepare ketamine in a gel base for rectal use. Gel formulations may provide more consistent mucosal contact and absorption than liquid solutions, though comparative bioavailability data remains limited.

Rectal Ketamine vs. Other Administration Routes

Route selection depends on how quickly sedation or analgesia is needed, whether IV access is available, and whether the patient can swallow or tolerate an injection. Compared with the other options covered in our ketamine treatment methods guide, rectal administration sits in the middle of the bioavailability and onset spectrum.

• Intravenous (IV): onset is immediate since the drug enters the bloodstream directly, making it the standard for surgical anesthesia and monitored infusions, but it requires reliable venous access.
• Intramuscular (IM): onset in 3-5 minutes, useful in emergency or field settings when IV access is not yet established.
• Oral (swallowed): bioavailability of 17-24 percent and onset of 20-45 minutes, the slowest of the routes discussed here.
• Sublingual: bioavailability comparable to the rectal route, around 25-30 percent, with absorption occurring through the oral mucosa rather than the rectum.
• Rectal: bioavailability of 25-30 percent with onset in 10-20 minutes, chosen specifically when oral intake or IV access is not feasible.